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ABSTRACT
Tumour-derived p53 mutants are thought to have
acquired ‘gain-of-function’ properties that contrib-
ute to oncogenicity. We have tested the hypothesis
that p53 mutants suppress p53-target gene expres-
sion, leading to enhanced cellular growth. Silencing
of mutant p53 expression in several human cell lines
was found to lead to the upregulation of wild-type
p53-target genes such as p21, gadd45, PERP and
PTEN. The expression of these genes was also sup-
pressed in H1299-based isogenic cell lines expres-
sing various hot-spot p53 mutants, and silencing
of mutant p53, but not TAp73, abrogated the sup-
pression. Consistently, these hot-spot p53 mutants
were able to suppress a variety of p53-target gene
promoters. Analysis using the proto-type p21
promoter construct indicated that the p53-binding
sites are dispensable for mutant p53-mediated
suppression. However, treatment with the histone
deacetylase inhibitor trichostatin-A resulted in relief
of mutant p53-mediated suppression, suggesting
that mutant p53 may induce hypo-acetylation of
target gene promoters leading to the suppressive
effects. Finally, we show that stable down-
regulation of mutant p53 expression resulted in
reduced cellular colony growth in human cancer
cells, which was found to be due to the induction
of apoptosis. Together, the results demonstrate
another mechanism through which p53 mutants
could promote cellular growth.
INTRODUCTION
The p53 suppressor gene is mutated in  50% of all human
cancers (1–3). Mutations in p53 have been shown to
abrogate its cardinal functions in promoting apoptosis,
cell-cycle arrest and DNA repair, thereby leading to
cancer development and progression (1,2). Activation
of p53, which is a transcription factor, results in the
transactivation of many target genes that regulate these
biological processes. Thus, abrogation of DNA-binding
function of p53 results in amelioration of p53-dependent
transcription, and hence, target genes required for the
eﬃcient execution of the biological processes are not
activated. The signiﬁcance of the DNA-binding property
of p53 in regulating many of its biological functions is
highlighted by the large percentage ( 90%) of mutations
found in DNA-binding domain (DBD) of p53 in human
cancers (1,3). Of these, there are several hot-spot residues
such as R175, G245, R248, R249, R273 and R282 that
are more prone to mutations than others (1,3). R248
and R273 are DNA-contact mutants and R175, G245,
R249 and R282 are conformational mutants (4), and like
most other mutations found in the DBD, all of them have
compromised DNA-binding activity (1,5).
Mutated p53 is often overexpressed in tumour cells
(1,2,6), due to their inability to eﬀectively activate
MDM2, which negatively regulates p53 abundance (7,8).
Whether the accumulated p53 in tumour cells have any
speciﬁc functions supporting cellular growth has been
intensively researched recently. There is accumulating
evidence that mutant p53 may not only have lost the
tumour-suppressive functions but may have also acquired
additional pro-oncogenic properties (6,8), leading to the
concept that mutant p53 may have acquired novel
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several biochemical and biological functions of mutant
p53 that are independent of wild-type p53’s activities
were described. It was shown that mutant p53 could
transactivate oncogenic targets such as c-myc (9),
anti-apoptotic gene BAG-1 (10), growth-promoting genes
as asparagine synthetase and hTERT (11,12) and the
multi-drug resistance gp180 protein (MDR1) (13).
At the same time, not much is known if mutant p53 has
any negative, inhibitory role on common p53-target gene
expression. In this respect, only one report by Zalcenstein
et al. demonstrated that the p53 mutant R175H could
down-regulate the expression from the p53-dependent
CD95(FAS/APO-1) promoter (14). However, whether
such a phenomenon is universal and aﬀects the status of
other wild-type p53-target genes is unclear.
Recent ﬁndings have also suggested that activation
of mutant p53 by small molecules such as PRIMA-1 could
restore sequence-speciﬁc DNA binding and the active
conformation to mutant p53 proteins in vitro and in vivo
in living cells, leading to anti-tumour eﬀects, which
was dependent on the presence of mutant p53 (15,16).
Although PRIMA-1 reconstituted the wild-type function
of mutant p53, it cannot be excluded that mutant p53 may
have been involved in the suppression of p53-target gene
expression, and modulation of such an activity could also
be one reason for the activation of its tumour-suppressive
functions. There is insuﬃcient evidence to propose
a mechanism by which mutant p53 could have acquired
a ‘gain-of-function’ by down-regulating the classical
p53-target gene expression.
We thus asked whether mutant p53 would be able to
modulate the expression of classical wild-type p53 respon-
sive target genes. We report here that down-regulation
of mutant p53 expression in several human cancer cell
lines harbouring mutant p53 by siRNA-mediated silencing
induced the expression of p53-dependent apoptotic
and repair genes. Consistently, several p53-target genes
were found to be down-regulated in isogenic cell lines
stably expressing the various hot-spot p53 mutants, which
also correlated with down-regulation of p53-target gene
promoter activity by various mutant p53 expression
in transient transfection assays. Down-regulation of
target gene activity was found not to be dependent on
the presence of p53-binding sites, but was markedly
reduced in the presence of histone deacetylase (HDAC)
inhibitor trichostatin-A (TSA), suggesting that mutant
p53-mediated p53-target gene suppression is at least in
part due to hypo-acetylation of histones. Finally, silencing
of p53 expression in human cancer cells resulted in
reduction in cellular colony formation, indicating that
mutant p53 expression indeed could support cellular
growth. Thus, our ﬁnding suggests a novel function of
mutant p53 that can contribute to cancer progression.
MATERIALS AND METHODS
Cellculture andplasmids
The p53 null H1299 human lung cancer cell line and the
13 derivate isogenic cell lines expressing vector (pCDNA)
or the six hot-spot mutations (R175H, G245S, R248W,
R249S, R273H and R282 W) either as an arginine or a
proline polymorphic variant at codon 72 has been estab-
lished in the laboratory and described previously (5).
H1299 cells stably expressing the temperature-sensitive
p53 mutant either as an arginine or proline polymorphic
form at codon 72 has been previously established in the
laboratory and has been described (17). At 378C, these
cells express p53 in a mutant conformation, and are hence
functionally inactive. Upon temperature shift to 328C, the
p53 adopts a wild-type conformation and is active (17).
Mutant p53-expressing CNE-2 nasopharyngeal carci-
noma cells, T47D breast carcinoma cells and HUH-7
hepatoma cells are gift from Dr Hui K M. The human
pancreatic cancer cell line PaCL4 has a missense alteration
in one allele of p300 gene and the second allele is inacti-
vated, as determined in an analysis to identify cell lines
and tumours with p300 mutations (gift from Dr Levrero
M) (18,19). All cell lines were cultured in DMEM
containing 10% bovine fetal serum. All H1299-based
isogenic cell lines were also kept on G418 (800mg/ml).
All p53 mutant and wild-type p53 plasmids were
generated and have been described (5,17). P73DD,
which inhibits TAp73 function, has been described
(20). The following p53-target gene promoter-reporter
constructs were used in this study: p21-luciferase (luc),
gadd45-luc, p53AIP-1-luc, Bax-luc, Igfbp3-luc, p53R2-luc,
cyclinG1-luc and hTert-luc, and have been described
(5,20). p21-promoter deletion constructs 0-luc, 2-luc and
4-luc were gift from Dr Waﬁk el-Deiry, and have been
described (21).
Small-interfering (si) RNA against p53 (gac ucc agu ggu
aau cua), p73 (ggc aau aau cuc ucg cag u) or scrambled,
control siRNA (uuc ucc gaa cgu guc acg u) were obtained
(synthesized by Xeragon) and used for gene silencing
experiments.
Transfections andluciferase assays
Here, 2 10
5 cells (in 6-well dishes) were used in trans-
fection experiments with LIPOFECTAMINE PLUS-
Reagent, as per manufacturer’s protocols (Stratagene),
or by the calcium phosphate method. Both methods gave
similar results. The transcriptional activity of various
p53 constructs were determined by luciferase assays in
human H1299 cells and PaCL4 cells by transfecting the
various promoter constructs (0.5mg) with empty vector,
wild-type p53 (arginine or proline) or the various p53
mutant constructs (0.1mg) and b-galactosidase construct
(0.1mg). Luciferase activity was determined by chemilu-
minance and normalized against b-galactosidase activity
24h after transfections, as described (20). In experiments
where TSA (Upstate Biotech.) was added, cells were pre-
treated with TSA (100ng/ml) for 6h before transfection.
TSA was present during transfection and luciferase
activity was analysed 18h after transfection. All experi-
ments were done at least thrice independently and data
represents mean from one of the experiments.
For silencing gene expression, the indicated siRNA
(5mg) were transfected into cells using TransMessenger
Transfection Reagent as per manufacturer’s
2094 Nucleic Acids Research, 2007, Vol. 35, No. 6instruction (Qiagen). Cells were harvested for 48h after
transfection and used for RNA analysis.
Colony formationassay
HUH-7 and T47D cells were co-transfected with 1mg
pCDNA and 10mg of pSuper-based plasmid containing
oligonucleotide sequences for silencing p53 [as described
in ref. (22)] or control, scrambled sequences, with
Eﬀectene transfection reagent (Qiagen). Further controls
included cells without any transfection. Twenty-four
hours after transfection, medium was changed and cells
were selected on medium containing G418 (500mg/ml) for
14 days. Colonies were colored with crystal violet solution
(MERCK).
RNA extraction and RT-PCR
Total RNA was prepared from cells using TRIZOL
Reagent (Invitrogen) as per manufacturer’s instructions.
Total RNA (1–5mg) was converted into single-strand
cDNA using Superscript II (Invitrogen) as per manufac-
turer’s instructions. Semi-quantitative RT-PCR analysis
was performed under the following conditions: TAp73:
948C–50s, 728C–1min, 548C–50s for 31 cycles (expected
size 350bp); gapdh:9 4 8C–35s, 728C–70s, 548C–50s for 23
cycles (500bp); gadd45:9 4 8C–35s, 728C–40s, 538C–35s
for 30 cycles (454bp); p53:9 4 8C–30s, 728C–90s,
608C–30s for 30 cycles (587bp); p21:9 4 8C–50s,
728C–60s, 548C–50s for 30 cycles (331bp); PTEN:
958C–30s, 728C–75s, 558C–30s for 31 cycles (1153bp);
PERP:9 4 8C–50s, 728C–50s, 528C–50s for 34 cycles
(500bp); c-jun:9 5 8C–30s, 728C–30s, 648C–30s for
31 cycles (280bp); pig3:9 5 8C–30s, 708C–50s, 578C–30s
for 30 cycles (349bp); p53R2:9 4 8C–30s, 708C–70s, 548C–
40s for 30 cycles (1000bp). All reactions were preceded by
heating at 948C for 3min, and ended with heating at 728C
for 10min. Primers used in this study are as follows:
TAp73 for: 50-TCT GGA ACC AGA CAG CAC CT; rev:
50-GTG CTG GAC TGC TGG AAA GT; gapdh for:
50-ACC CCT TCA TTG ACC TCA AC; rev: 50–CAG
CGC CAG TAG AGG CAG; gadd45 for: 50-TTG GAG
GAA TTC TCG GCT GGA GAG CAG AGG; rev:
50CCA TTG ATC CAT GTA ACT TTC CCG GCA; p53
for: 50-AGG AGC CGC AGT CAG ATC; rev: 50- ACT
CGG ATA AGA TGC TGA G; p21 for: 50-CGA CTG
TGA TGC GCT AAT GG; rev: 50CCG TTT TCG ACC
CTG AGA; PTEN for: 50-GCCATCATCAAAGAGA
TCGTT; rev: 50GGATCAGAGTCAGTGG; PERP for:
50-TACTCAGCGCCATCGCCTTC; rev: 50-TGTGTAG
AAGTACCTGGGCTTG; c-jun for: 50-ATG CCC TCA
ACG CCT CGT TCC TCC; rev: 50-CTG CTC GTC GGT
CAC GTT CTT CTT GGG; pig3 for:50-GTG CAC TTT
GAC AAG CCG GGA GGA; rev: 50-CAG CCT GGG
TCA GGG TCA ATC CCT; p53R2 for: 50-ATGGGCGA
CCCGGAAAGGCCGGAA;rev: 50-TCTGCATCCAAG
GTGAAGACGTT.
Immunoblot analysis
Cell lysates were prepared as described (23). Protein
lysates were analysed by immunoblotting using anti-p53
(clone DO-1), gadd45, PTEN and p21 (Santa Cruz) and
anti-Actin (Sigma) antibodies, as described (23). Detection
was performed using enhanced chemiluminescent reagent
(Amersham).
Celldeathanalysis
Cell death was determined by analysing the population
of cells with a sub-G1 DNA content, by staining with
propidium iodide (PI). Brieﬂy, cells were harvested 3–5
days after siRNA transfection, washed once in PBS
and ﬁxed in 70% ethanol overnight before being stained
with PI for analysis of the DNA-content. All analyses
were performed by ﬂow cytometry in duplicates and twice
independently.
RESULTS
Silencing of p53expression results in upregulation
ofp53-target genesin several human cancer cell lines
expressing mutantp53
We ﬁrst tested the hypothesis that silencing of mutant
p53 expression will aﬀect the expression of endogenous
p53-target genes. To this end, we utilized three human
cancer cell lines, namely the HUH-7 hepatoma cell line
which harbours the A220G mutation; the T47D breast
cancer cell line which carries the C194T mutation and
the CNE-2 nasopahryngeal carcinoma cell line that
harbours the R280T mutation (24–26). p53 mRNA
levels were reduced upon siRNA-mediated silencing
using p53-speciﬁc siRNA and not in control scrambled
siRNA-transfected or untransfected cells in all cases
(Figure 1A–C). Concomitant to reduction in p53 levels,
the levels of gadd45, PTEN and PERP were upregulated
in HUH-7 cells (Figure 1A). The upregulation of PTEN
and gadd45 was also conﬁrmed at the protein level by
immunoblotting (Figure 1B). However, the expression
levels of other p53-target genes such as p21 and pig3 were
unaltered upon p53 silencing in HUH-7 cells (Figure 1A
and B). This variable upregulation of p53-target genes was
also noticed in the other two cell lines. p53 silencing
resulted in upregulation of gadd45 and to some extent
of p21 in T47D cells, and only marginal upregulation
of p21 in CNE-2 cells (Figure 1C). The levels of pig3 did
not change in both cells lines whereas gadd45 remained
unchanged in CNE-2 cells (Figure 1C). This eﬀect of
increase in expression of various genes was restricted to
p53-target genes as expression of unrelated genes such
as TAp73 and c-jun were unaltered by silencing of p53
(Figure 1D). It was interesting to note that TAp73
expression was naturally silenced in HUH-7 cells, and
together with the absence of any change in TAp73 levels in
the other two cell lines, the data exclude the possibility
that the increase in the expression of p53-target genes
upon p53 silencing was due to relief of mutant
p53-mediated suppression of p73 function.
H1299-based isogenic cell lines expressing hot-spot p53
mutants express reduced levels ofp53-target genes, whose
expressioncanbeinducedbysilencingmutantp53expression
The results obtained from the human cancer cell lines
expressing endogenous mutant p53 indicated that mutant
Nucleic Acids Research, 2007, Vol. 35, No. 6 2095p53 may be actively silencing p53-target gene expression.
To further investigate this possibility, we analysed the
expression status of several p53-target genes such as p21,
gadd45 and p53R2, in a panel of H1299-based isogenic
cell lines stably expressing the six hot-spot p53 mutants,
which has been generated in our previous study (5).
The isogenic cell lines express approximately equal
amounts of the six commonly found human cancer-
derived hot-spot mutations such as R175H, G245S,
R248W, R249S, R273H and R282W, in either of
the polymorphic forms of the common polymorphism
at codon 72, i.e. arginine or proline (R or P) (5). H1299
cells expressing empty expression pcDNA vector
or temperature-sensitive mutant p53 in either the R or P
forms and cultured at 328C, during which the p53-target
genes are activated (19), were used as positive controls.
Using these cell lines, we noticed that the p53-target
gene expression was markedly reduced in almost
all mutant-p53-expressing cell lines compared to the
vector-expressing cell line, whereas expression of active
wild-type p53 resulted in induction of these target
genes (Figure 2A). The reduction was more pronounced
with respect to p21 and gadd45 levels, whereas the
reduction of p53R2 levels was less pronounced.
Although there were variations in the levels of p53R2
expression between cells expressing either the R or P
form of various p53 mutants, all the cell lines had
reduced p53R2 levels compared to wild-type p53-expres-
sing cells (Figure 2A), indicating that the eﬀect may be
general and attributable to mutant p53. The levels of p53
were almost similar in all cell lines, excluding any
possibility that p53 levels may inﬂuence the expression
of the target genes (Figure 2B, and data not shown).
Moreover, expression of the multi-drug resistance gene-1
(mdr-1) was not suppressed but elevated in cell lines
expressing the p53 mutants (Figure 2A, lower panel).
These data suggested that mutant p53 expres-
sion indeed results in the suppression of p53-target gene
expression.
We thus analysed the eﬀects of silencing mutant p53
expression in some of these cell lines. To this end, cell lines
expressing p53 mutants R273 (in the arginine or proline
form) were utilized. p53 expression was silenced by
siRNA-mediated silencing, which resulted in an increase
in p21 and gadd45 levels in the 273 mutant p53-expressing
cell lines, but not in vector-expressing cell lines
(Figure 2B). Similar to the RT-PCR data, immunoblot
analysis indicated that the levels of gadd45 were reduced
in mutant p53 cells compared to vector-expressing cells
that were untransfected or transfected with scrambled
siRNA (Figure 2C). By contrast, the levels of gadd45
were almost comparable between vector-expressing cells
and those expressing mutant p53 in which p53 expression
was silenced (Figure 2C), indicating that expression
of mutant p53 indeed resulted in the suppression of
p53-target gene expression.
As mutant p53 was shown to inactivate TAp73
activity (27,28), the observed decrease in p53-target gene
expression in cells expressing mutant p53 could be
due to inactivation of p73 function. To investigate this
possibility, we silenced the expression of TAp73 in H1299
cells (control vector-expressing cells) by p73-speciﬁc
siRNA (Figure 2D). Transfection of scrambled siRNA
resulted in marginal increase in gadd45 levels (Figure 2D).
However, silencing of p73 expression did not lead to a
decrease in the levels of p21 and gadd45 in these cells
(Figure 2D). In addition, we expressed the dominant
negative p73DD protein, which is able to inhibit TAp73
activity by binding to it (29). Expression of p73DD did
not also cause a reduction of p21 and gadd45 levels,
conﬁrming that decrease in TAp73 levels or activity are
not causal to lower levels of p53-target gene expression
in mutant p53-expressing cell lines. Moreover, these
results suggest that down-regulation of p53-target gene
expression may be a direct consequence of mutant
p53 expression.
Figure 1. Silencing of mutant p53 expression results in upregulation of
p53-target gene expression. (A and B) Mutant p53 harbouring HUH-7
hepatoma cells (A220G) were untransfected ( ) or transfected with
either control scrambled siRNA or p53-speciﬁc siRNA. Cells were
collected 48h later for mRNA analysis of the indicated target genes by
reverse-transcriptase (RT) PCR reaction (A) or by immunoblotting
with the speciﬁc antibodies (B). (C) RT-PCR target gene analysis was
similarly performed in T47D breast cancer cells (C194T) (left panel)
and CNE-2 nasopharyngeal carcinoma cells (R280T) (right panel).
(D) mRNA analysis shows direct comparison of p53-regulated gadd45
gene expression as well as p53-independent TAp73 and c-Jun expression
levels in all three cell lines.
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activity of p53-targetgenes
To understand the mechanism of down-regulation
of p53-target genes by mutant p53, we performed transient
co-transfection experiments to analyse the eﬀects of
various hot-spot p53 mutant constructs on p53-target
gene promoter activity, in H1299 cells. We utilized seven
p53-dependent promoters, including p21, GADD45,
p53AIP-1, BAX, IGFBP3, cyclinG1 and p53R2
(Figure 3A–G). Expression of wild-type p53 in either the
proline or arginine polymorphic variant resulted in
massive activation of all promoters (Figure 3A–G). By
contrast, expression of the six hot-spot p53 mutants in
either of the polymorphic forms generally resulted in the
suppression of promoter activity throughout, compared
to vector (Figure 3A–G), consistent with the ﬁndings
obtained with endogenous levels of target genes.
The extent of suppression was dependent on the kind of
mutation and the promoters used in the experiments.
It should be noted that although there were variations
in the levels of suppression of target gene promoters
between cells expressing either the R or P form of various
p53 mutants, expression of all forms of mutants led to a
decrease in target gene promoter activity (Figure 3A–G),
indicating that the eﬀect may be general and attributable
to mutant p53. We have excluded the possibility that
the diﬀerences in p53 levels are causal to the diﬀerences
in promoter activity, as all mutant p53 constructs
were expressed to about equal extents (Figure 3I, showing
representative results). Moreover, this suppressive eﬀect
was not unspeciﬁc as it was not observed with the hTERT
promoter, which is generally suppressed by wild-type
p53 (20). Although wild-type p53 suppressed hTERT
promoter activity, most mutant p53 did not (Figure 3H).
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Figure 2. Mutant p53 expression leads to suppression of p53-target gene expression, which is relieved upon silencing of mutant p53 expression.
(A) H1299-based isogeneic cell lines stably expressing the six hot-spot p53 mutants (i.e. 175, 245, 248, 249, 273 and 282) either in the proline (Pro) or
arginine (Arg) codon 72 polymorphic form were analysed for steady-state p53-target gene expression levels, as indicated, by reverse-transcriptase
PCR reaction. H1299-cells stably expressing the temperature-sensitive p53 mutants, which adopt a wild-type conformation at 328C, were grown at
328C and used as positive controls for p53-target gene activation (WT-Pro and Arg). Levels of mdr-1 were also evaluated. (B and C) H1299-cells
expressing p53 mutant R273H in the proline (P) or arginine (R) codon 72 polymorphic form were transfected with either control scrambled siRNA
or p53-speciﬁc siRNA or left untransfected ( ). Cells were collected 48h later for mRNA analysis of the indicated target genes by RT-PCR reaction
(B) or by immunoblot analysis (C). (D) Vector-expressing H1299 cells were transfected with control scrambled siRNA, p73-speciﬁc siRNA, p73DD
cDNA or left untransfected ( ), and the levels of target genes were analysed by RT-PCR reaction.
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2098 Nucleic Acids Research, 2007, Vol. 35, No. 6Thus, the data indicate that various hot-spot p53 mutants
have the ability to suppress the expression from p53-target
gene promoters.
Presence of p53-binding site onp21 promoter
is notrequired fordown-regulation by mutantp53
It was interesting to note that all the mutants used in this
study are DNA-binding mutants and hence, do not have
the property to bind DNA in a sequence-speciﬁc manner
(1). However, the results suggest that the suppression by
mutant p53 is speciﬁc to p53-target gene promoters.
Hence, we investigated if the p53-binding sites on the
promoters are required for the suppression. To this end,
we utilized the proto-type promoter constructs from the
p21 promoter having (0-Luc) or lacking one or both of
the p53- binding sites (2-Luc or 4-Luc, respectively)
(Figure 4A) (21). Lack of one p53-binding site did not
aﬀect the ability of wild-type p53 to activate the promoter
or the ability of representative p53 mutants (R248 and
R273) to suppress it (Figure 4B, middle panel). However,
although deletion of both p53-binding sites abrogated
wild-type p53’s ability to activate the promoter, the
mutant p53 were still able to suppress this activity
(Figure 4B, rightmost panel). Thus, the results suggest
that the presence of p53-binding sites are not absolutely
essential for mutant p53 to down regulate p53-target gene
promoters.
Treatment withTrichostatin Arelieves mutant
p53-mediated suppression ofp53-target genes
One possible mechanism of gene suppression is hypo-
acetylation of histones by histone deacetylases (HDAC),
and wild-type p53 has been shown to suppress several gene
promoters by recruitment of HDACs (30). We therefore
explored the possibility that p53 mutants exerted their
suppressive eﬀects on p53-target genes by aﬀecting the
chromatin acetylation status. To this end, we ﬁrst utilized
the HDAC inhibitor, Trichostatin A (TSA) (31), and
evaluated its eﬀect on the ability of mutant p53 (R248 and
R273) to suppress the p53AIP-1and p21 promoters. Treat-
ment with TSA resulted in a massive induction of the
promoter activity even in the presence of the p53 mutants
(Figure 5A), compared to TSA-untreated cells where there
was a consistent suppression by the mutants (Figure 5A).
There was also a slight increase in the promoter activity of
vector-transfected cells treated with TSA (Figure 5A).
However, the eﬀect of increase in promoter activity was
much more pronounced when mutant p53 was transfected,
suggesting that TSA-mediated relief of suppression was at
least partially dependent on the presence of mutant p53.
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Figure 4. Presence of p53 binding sites on p21 promoter is not required for down-regulation by mutant p53. (A) Schematic of p21 promoter
indicating the position of the p53 binding sites (S1 and S2) as described (21). (B) Luciferase reporter assays were preformed by transfecting vector,
wild-type p53, or the indicated p53 mutant cDNA constructs into H1299 cells as described, with the various p21 promoter constructs. Transfections
were carried out in triplicates and at least three independent times and the standard deviations are indicated.
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of all six hot-spot mutants (in both the proline or arginine
polymorphic variations) on the gadd45 promoter. Treat-
ment with TSA again resulted in the relief of suppression
of promoter activity, though to varying extents depending
on the p53 mutants used, as well as the polymorphic
status (Figure 5B).
To evaluate if treatment with TSA will aﬀect the levels
of endogenous p53-target genes in mutant p53-expressing
cells, we analysed the levels of both p21 and PTEN
in several H1299-based isogenic cells lines expressing
various mutant p53 in either the proline or arginine
polymorphic forms. Treatment with TSA resulted in
a signiﬁcant increase in the levels of p21 in most of the
cell lines expressing mutant p53 (Figure 5C, top panel).
This was in contrast to vector-expressing cells in which
TSA caused a down- regulation of p21 levels (Figure 5C,
top panel). Similarly, expression of PTEN was elevated
upon TSA treatment in all mutant p53-expressing cells
lines, albeit to diﬀerent extents (Figure 5C, lower panel).
However, the increase of PTEN levels in vector-expressing
cells were marginal and not of the magnitude as observed
with mutant p53-expressing cells (Figure 5C, lower panel).
It should be noted that cells expressing p53 mutants in
either the proline or arginine polymorphic forms were
responsive to TSA treatment, though to varying extents,
suggesting that the polymorphism may not be crucial in
mutant p53’s ability to suppress target gene expression.
Moreover, consistent with the promoter activity, diﬀerent
p53 mutants had varying abilities to suppress target gene
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Figure 5. Treatment with Trichostatin A relieves mutant p53-mediated suppression of p53-target genes, which is reduced in cells lacking p300.
(A and B) Luciferase reporter assays were performed as described above using the indicated p53 constructs in the presence (þ) or absence ( )o f
trichostatin-A (TSA). Cells were pre-treated with TSA (100ng/ml) for 6h before transfection and TSA was present during transfection and luciferase
activity was analysed 18h after transfection. Promoter activity was determined using the p53AIP-1, p21 (A) and the gadd45 promoter constructs (B)
The level of luciferase activity in mutant p53-transfected cells are shown as the percentage activity compared to the vector-transfected cells, which
was set at 100%. (C) H1299-based isogenic cells lines stably expressing the indicated mutant p53 in either the proline (P) or arginine (R) codon 72
polymorphic form were treated in the presence (þ) or absence ( ) of TSA as described for 18h and the levels of p21 and PTEN mRNA were
analysed by reverse-transcriptase PCR reaction. (D) p53-target gene promoter activity was determined using the p53AIP-1 or p21 promoter
constructs in p300 deﬁcient (pancreatic cancer cell line PaCL4) or proﬁcient (lung adenocarcinoma H1299) cells.
2100 Nucleic Acids Research, 2007, Vol. 35, No. 6expression, which upon TSA treatment, resulted in
upregulation of target genes to varying extents.
Together, the data suggest that mutant p53-mediated
p53-target gene suppression is at least in part due to hypo-
acetylation of histones.
p300 is a transcriptional co-activator that is involved
in regulating acetylation of proteins (32). To conﬁrm
the role of histone deacetylation in the down-regulation
of promoters by mutant p53, we used the human
pancreatic PaCL4 cell line in which p300 is deleted,
and exhibit reduced histone acetylation activity (18).
Two p53 mutants (R248 and R273) were used to evaluate
their ability to suppress p53AIP-1 and p21 promoter
activity, in both H1299 and PaCL4 cells. Whereas
the mutant p53 consistently suppressed promoter activity
to a signiﬁcant extent in H1299 cells, this eﬀect was
reproducibly less pronounced in PaCL4 cells (Figure 5D).
These data thus support the hypothesis that mutant p53
probably down-regulates p53-target gene promoters by
decreasing the acetylation status.
Knock-down of mutantp53 expression results in
suppression of cellular colony formationdue
to increased apoptosis
Since silencing of mutant p53 expression led to the induc-
tion of p53-target genes involved in growth arrest and
apoptosis, we evaluated if knock-down of endogenous
mutant p53 expression would also aﬀect cellular growth.
Hence, we silenced p53 expression in HUH-7 cells which
harbours the A220G mutation in p53 and in T47D cells
that carry the C194T mutation, and where silencing led to
increased expression of p53-target genes (Figure 1A–C).
Plasmid-based scrambled control siRNA and p53-speciﬁc
siRNA were transfected and cells were selected for
 2 weeks to monitor cellular colony formation, which
reﬂects the long-term propensity of cells to grow. Parallel
cultures were evaluated for speciﬁc and eﬀective silencing
of p53 expression (Figure 6A, shown for HUH-7).
Whereas scrambled siRNA did not aﬀect the growth of
both cell lines, p53-speciﬁc siRNA expression resulted
in markedly reduced number of colonies in both cases
(Figure 6B, upper panel showing representative results).
Absence of any transfection and subsequent selection
resulted in no surviving colonies, conﬁrming the eﬃcacy of
the selection procedure. Enumeration of cellular colonies
indicated that there was a signiﬁcant decrease in the
number of colonies upon silencing of p53 expression
(HUH-7––control versus p53 siRNA: 407 versus 133;
P¼0.0073 and T47D—control versus p53 siRNA: 406
versus 103; P¼0.0133).
We ﬁnally evaluated if the reduction in colony forma-
tion upon silencing p53 expression was due to elevated
apoptosis. Comparison of apoptotic cells with a sub-G1
DNA content indicated that there was a signiﬁcant
increase when p53 siRNA was transfected compared to
scrambled siRNA (Figure 6C for HUH-7 cells: % sub-G1
cells —scr. siRNA versus p53 siRNA: for 100nM—5.0
versus 24.5; for 200nM: 18.3 versus 44.1). Together,
the data suggest that suppression of mutant p53
expression inhibits cellular growth probably via induction
of apoptosis.
DISCUSSION
The results presented here demonstrate that expression
of mutant p53, which does not have the ability to
transactivate p53-target gene expression, results in down-
regulation of various p53-target genes in several cell lines.
Silencing of mutant p53 expression led to relief of this
suppression and thus, activation of various p53-target
genes. Cellular colony formation was reduced upon
silencing of mutant p53 expression due to increased cell
death, correlating with upregulation of p53-target gene
expression. Thus, the down-regulation of p53-target genes
by mutant p53 appears to be a general phenomenon,
and hence, may constitute one mechanism for the gain
of function of mutant p53.
It is intriguing that not much attention has been paid
to this phenomenon, which is quite obvious upon closer
analysis of results of promoter-reporter assays. Such
assays have been traditionally used and most researchers
have concluded from these that mutant p53 do not
have the ability to activate the promoters of p53-target
genes. However, the down-regulation has somewhat gone
unnoticed by many, as it is not striking at ﬁrst glance.
However, careful analysis of a recently published article
indicated that expression of various hot-spot p53 mutants
indeed resulted in down-regulation of the p21 promoter
[Supplementary Data of ref. (33)—Table 2]. Moreover,
consistent with an earlier report that mutant p53 could
suppress CD95 promoter activity, the data presented
here strongly argue that suppression of p53-target gene
expression could be a general mechanism by which mutant
p53 could support oncogenesis.
The upregulation of p53-target genes upon silencing
of mutant p53 expression was not unspeciﬁc, as expression
of other genes such as c-jun, TAp73 and mdr-1 was not
aﬀected. Furthermore, p53 mutants were found to activate
mdr-1 gene expression and the hTERT promoter activity
as has been previously reported (12,13). Moreover, this
phenomenon of suppression required the presence of
mutant p53, as cells devoid of p53 did not show changes
in the levels of target genes, and cellular colony growth
was not aﬀected upon p53 silencing in these cells,
indicating that the expression of mutant p53 was essential.
However, there are several variations that we observed in
our studies: the extent to which the various p53-target
genes were upregulated upon p53 silencing and the magni-
tude of target gene suppression by the proline or arginine
polymorphic variants of mutant p53. For example, most
of the genes analysed were upregulated in HUH-7 cells,
whereas not all of them were upregulated in CNE-2 cells,
thereby reﬂecting the cell-to-cell variation. It could be also
that diﬀerent p53 mutants have diﬀerential capacity to
suppress target genes. Besides, although all the mutants
had the ability to suppress gene expression, there were
variations between the arginine and proline polymorphic
forms, similar to that observed with wild-type p53 forms,
which have also been shown to diﬀerentially regulate
Nucleic Acids Research, 2007, Vol. 35, No. 6 2101Figure 6. Silencing of p53 expression results in reduced colony formation and elevated cell death. (A and B) p53 expression was silenced as described
in HUH-7 and T47D cells using pSuper-based control or p53-speciﬁc siRNA, or were left untransfected. Cells were selected for two weeks on G418.
Parallel cultures were used for semi-quantitative RT-PCR analysis of p53 expression status (representative results shown for HUH-7 cells) (A) and
colonies were visualized by staining with crystal violet solution (B, upper panel). All experiments were performed at least thrice independently and
representative results are shown. Colonies were counted both manually and using colony count software. Similar results were obtained using both
methods. Data are presented as the mean SD error of the mean. (C) Cell death was analysed by measuring the sub-G1 DNA content reﬂective of
apoptotic cells, by ﬂow cytometry. HUH-7 cells were transfected with scrambled or p53 siRNA (100 or 200nM) and the percentage cell death was
determined 5 days after transfection. Representative results are shown.
2102 Nucleic Acids Research, 2007, Vol. 35, No. 6target gene expression (17). However, we were unable
to observe a general pattern if either of the polymorphic
forms could better suppress target gene expression
than the other. The cause of this variation, which was
also apparent in experiments in which cells were treated
with TSA, is not clear and warrants further investigation.
Nonetheless, the phenomenon of mutant p53-mediated
suppression of p53-target genes appears to be consistent
in most mutant p53-containing cell lines examined.
While our work was in progress, two recent publications
reported that suppression of mutant p53 expression
could indeed lead to inhibition of cellular growth. Bossi
et al. utilized several human cancer cell lines harbouring
mutant p53 and found that silencing of mutant p53
expression led to a reduction in tumour malignancy (34).
The other report indicated that depletion of mutant
p53 expression resulted in the activation of p21, bax and
PIG3 promoter activity and led to cellular cytotoxicity
(35). In addition, similar suppression of p53 expression
in H1299 cells stably expressing the mutant R175H
p53 was also shown to decrease cellular growth (36).
Together, these data support our ﬁndings and suggest that
suppression of mutant p53 expression may be one
important way to relief the mutant p53-mediated down-
regulation of p53-target gene expression, and hence, could
lead to inhibition of cellular growth.
It is at present unclear whether mutant p53-mediated
suppression of p53-target gene expression is direct.
As mutant p53 was shown to inactivate TAp73 activity
(27,28), the observed decrease in p53-target gene expres-
sion in cells expressing mutant p53 could be due
to inactivation of p73 function. However, we have
excluded this possibility as siRNA-mediated silencing of
TAp73 expression and inactivation of TAp73 activity by
expression of the dominant negative p73DD protein did
not lead to a decrease of expression of p53-target genes,
further indicating that down-regulation of p53-target
gene expression is a direct consequence of mutant p53
expression and not due to p73 inactivation. Wild-type
p53 has been shown to activate target genes by binding
to p53-speciﬁc binding sequences found in the target
gene promoters (21). However, investigations with
the prototype p21 promoter indicated that both the
p53-binding sites are dispensable for mutant p53-mediated
suppression. It is thus not clear how mutant p53 is able
to recognize target gene promoters speciﬁcally.
Because all the p53 mutants used in this study have lost
their sequence-speciﬁc DNA-binding ability (data not
shown), the ﬁndings suggest that mutant p53 may still
bind to p53-target gene promoters at diﬀerent positions,
independent of their DBD, or aﬀect gene regulation by
other means. Support for this hypothesis comes from
several studies. First, it was shown that mutant p53 may
promote gene ampliﬁcation by activating topoisomerase I,
leading to genomic instability (37). Next, Zalcenstein et al.
demonstrated that mutant R175H p53 was able to bind to
CD95 promoter sequences in the region distinct from the
p53-binding sites where wild-type p53 binds (14).
Consistently, Gohler et al. suggested that mutant p53
binds selectively and with high aﬃnity to non-B DNA,
which was found to be dependent on the stereo-speciﬁc
conﬁguration of the DNA, and not on DNA sequence
(38). It is not clear at present if there is a consensus
sequence or speciﬁc conﬁguration in all the p53-target
gene promoters to which mutant p53 could bind, and
further investigations are required to elucidate this
possibility.
Nonetheless, the mechanism of mutant p53-mediated
suppression of target gene expression appears to partly
depend on HDAC activity. Treatment of cells with
the HDAC inhibitor TSA resulted in relief of suppression
that was dependent on the presence of mutant p53.
It was reported that TSA could also initiate p53-like
functions by inducing a variety of p53-inducible genes in
a p53-independent manner (31). Thus, it is possible that
both mutant p53-dependent relief of down-regulation and
p53-independent transactivation mechanisms may work
simultaneously to activate these target genes. However,
comparison of promoter activity upon TSA treatment
in vector and mutant p53 expressing cells indicated
that release from suppression was much stronger in
presence of mutant p53, thereby excluding non-speciﬁc
p53-independent eﬀects as a major causal mechanism
at work. Recent data by Blagosklonny et al. who had
utilized another HDAC inhibitor, FR901228, also support
our ﬁndings (35). Treatment with FR901228 resulted
in the induction of mRNA of p53-target genes, and
consequent cytotoxicity, speciﬁcally in cells expressing
mutant p53 (35). Furthermore, our studies demonstrated
that mutant p53-mediated suppression was less pro-
nounced in tumour cells lacking p300, the transcriptional
co-activator protein that plays a central role in
co-ordinating and integrating multiple signal-dependent
events (32). However, we were unable to observe
a synergistic increase in target gene suppression by
co-transfection of p300 with mutant p53 (data not
shown). Thus, p300 may be required but not suﬃcient
for mutant p53-dependent down-regulation of p53-target
gene expression, which occurs at least in part by
decreasing the acetylation status.
Taken together, the results presented here propose
another mechanism through which mutant p53 may con-
tribute to unregulated cellular growth and oncogenesis.
Together with the recent reports demonstrating mutant
p53’s ability to support cellular viability, the presence
of the overexpressed mutant p53 in tumour cells may
be a good therapeutic target for clinical intervention.
Future studies should thus be aimed at eﬃciently
suppressing mutant p53 expression in human tumours in
in vivo models to evaluate the eﬃcacy of ‘anti-mutant p53
therapy’.
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